Skip to main content

CellaVision announces preliminary first quarter results 2023

First quarter preliminary results 2023

  • Net sales decreased by 14% to SEK 139 m (162)
  • EBITDA margin amounted to 25% (36)
“Coming off two soft quarters in a row, temporary inventory reductions at distribution partners due to the uncertain economic climate had an adverse effect on the first quarter 2023. Post-COVID-implications in the important market of China has further slowed growth. These challenges have resulted in a deviation from our growth ambition.
However, distribution partners indicate that the underlying growing demand for digital cell morphology remains and that inventory levels have now normalized. We therefore expect our order pattern to improve throughout 2023.
Increased cost control has been implemented but investments in research and development will be continued to support our long-term financial ambition.”

Simon Østergaard, President & CEO